Breast Cancer Predisposition Syndromes (Q37785234)

23 August 2017

title

Breast cancer predisposition syndromes (English)

1 reference

23 August 2017

Breast Cancer Predisposition Syndromes (English)

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

6 July 2024

1 reference

genetic predisposition to disease

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816575

6 July 2024

2

Susan M Domchek

1 reference

23 August 2017

Deborah Hemel

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20816575

6 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0889858810000936?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

https://api.elsevier.com/content/article/PII:S0889858810000936?httpAccept=text/plain

6 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Hematology / Oncology Clinics of North America

6 July 2024

published in

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

799-814

1 reference

Biallelic inactivation of BRCA2 in Fanconi anemia

23 August 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.1073834

Cancer statistics, 2009

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement

1

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

6 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations

6 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families

6 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germline mutations in the TP53 gene

6 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites

6 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

High frequency of de novo mutations in Li-Fraumeni syndrome

6 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?

6 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome

6 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Screening for germ line TP53 mutations in breast cancer patients

6 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk

6 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives

6 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.

6 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.

6 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

6 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation

6 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Will the real Cowden syndrome please stand up: revised diagnostic criteria

6 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

PTEN hamartoma tumor syndrome: an overview

6 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Cowden's disease: a cutaneous marker of breast cancer

6 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations

6 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer

6 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

6 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

6 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

6 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Prevalence and Predictors ofBRCA1andBRCA2Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years

6 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

6 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer

6 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

6 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

6 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Meta-analysis of BRCA1 and BRCA2 penetrance

6 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Variation of breast cancer risk among BRCA1/2 carriers

6 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation

6 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

6 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

6 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Selecting a BRCA risk assessment model for use in a familial cancer clinic

6 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families

6 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition

6 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

6 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

6 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.

6 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

6 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.

6 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers

6 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

6 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

6 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

6 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

6 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

6 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

6 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group

6 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.

6 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

6 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

6 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

6 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

6 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers

6 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study

6 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study

6 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.

6 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Survival patterns after oophorectomy in premenopausal women: a population-based cohort study.

6 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

6 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers

6 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy

6 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers

6 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

6 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

6 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

6 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

6 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

6 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Prognosis of BRCA-associated breast cancer: a summary of evidence

6 July 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Can genetic testing guide treatment in breast cancer?

6 July 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

6 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

6 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

6 July 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.HOC.2010.06.004

6 July 2024

Identifiers

1 reference

23 August 2017

1 reference